Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.

Purdue researchers developed a mass spectrometry platform that accelerates cancer drug discovery by integrating synthesis, ...

Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed ...

A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how ...

New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

A new study has identified a more precise and effective way to prevent cancer from spreading to the brain. The paper, ...

A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 patients with RAS mutations.

Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and ...

Cancer drug development has never moved faster. Yet, for too many patients, the next treatment decision still begins with ...

The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.

Could the next big cancer drug come from global health research? - COMMENT: The next blockbuster treatment drug might not, in fact, come from research into cancer itself but from research into a ...

(CVM) slumped more than 7% in pre-market trading on Monday, with the stock tracking its fifth straight session of decline, ...